1989
DOI: 10.1212/wnl.39.4.590
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of single dose meperidine, butorphanol, and dihydroergotamine in the treatment of vascular headache

Abstract: We treated 64 emergency room patients with a primary vascular headache with dihydroergotamine (DHE), meperidine, or butorphanol. Post-treatment pain scores were lowest in the DHE group (p less than 0.01). Eight of 21 patients receiving DHE had greater than 90% reduction in pain compared with three of 19 patients receiving butorphanol and none of 22 receiving meperidine.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
51
0

Year Published

1992
1992
2005
2005

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 66 publications
(51 citation statements)
references
References 0 publications
0
51
0
Order By: Relevance
“…Two independent reviewers identified 53 abstracts as potentially relevant to this review. Independent review of the full manuscripts of the 53 potentially relevant studies resulted in 11 studies being included in this review [12][13][14][15][16][17][18][19][20][21][22] (Figure 1). There were no disagreements between 2 independent reviewers about inclusion of studies in the review.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…Two independent reviewers identified 53 abstracts as potentially relevant to this review. Independent review of the full manuscripts of the 53 potentially relevant studies resulted in 11 studies being included in this review [12][13][14][15][16][17][18][19][20][21][22] (Figure 1). There were no disagreements between 2 independent reviewers about inclusion of studies in the review.…”
Section: Resultsmentioning
confidence: 99%
“…[15][16][17][18][19][20][21][22] Because of significant heterogeneity in study methodology (Table), particularly with regard to the comparison treatments, studies were not pooled statistically. The results, however, are summarized below and presented in Figures 2 to 9.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Clinically, DHE has been proven to be highly effective in treating acute migraine with or without aura [37][38][39] and may be administered at any time during the attack, including the aura, in contrast to the triptans. Repetitive IV DHE is a treatment of choice for status migrainous [28] and is particularly effective for the treatment of chronic daily headache (transformed or chronic migraine) and analgesic rebound headache.…”
Section: The Clinical Role Of Dihydroergotaminementioning
confidence: 99%
“…Dihydroergotamine (DHE) has had a role in the treatment of migraine for many years and most protocols of treatment recommend the inclusion of DHE for patients who are not chronic abusers of ergotamine (3,4,(14)(15)(16) . Alternatives to oral tablets should be used in preference, considering that nausea is a common side effect.…”
Section: Introductionmentioning
confidence: 99%